Keywords
Healthcare Reform
Implementation Effect
Medical Insurance Synergy
Categories
How to Cite
Abstract
Objective
As a core initiative of China's healthcare reform, the policy of "separation of prescribing and dispensing" (SPD) aims to break the drug-supported medical system, standardize medical practices, reduce patients' medication burden, and promote high-quality development of healthcare. However, existing research lacks a holistic analysis of the policy's evolution and its long-term effects, especially in the context of urban–rural disparities and population mobility. This study systematically examines the policy logic, implementation effectiveness, and optimization pathways of SPD to support decision-making in medical governance.
Methods
Guided by problem-oriented and systematic thinking, this study combines quantitative analysis of policy texts with multi-dimensional empirical data. It delineates the four-stage evolution of SPD ("Exploratory Launch – Deepened Pilots – Comprehensive Breakthroughs – Collaborative Deepening"), constructs a three-dimensional evaluation system, and analyzes core contradictions with emphasis on urban–rural divides and cross-regional healthcare challenges.
Results
The study reveals the internal logic and dynamic mechanisms of SPD's phased evolution. Evaluation results indicate that the reform has contributed to drug price regulation and resource optimization, but long-term issues such as service accessibility and systemic innovation remain insufficiently addressed. Key challenges include coordination between medical insurance systems and the impact of population mobility, highlighting the need for integrated institutional design.
Conclusions
The study proposes a "three-in-one" pathway integrating "interest severance, medical insurance synergy, and regulatory innovation" to optimize SPD. By refining policy adjustments and strengthening systemic coordination, the reform can better balance stakeholder interests, improve the efficiency and equity of the healthcare system, and offer theoretical and practical support for advancing China's medical reform.
References
[1] Gong, Hanxiang, et al. "China's coordinated tripartite medical reform: strategic balancing of interests among pharmaceuticals, healthcare, and health insurance." Frontiers in Public Health 13 (2025): 1591358.
[2] Mao, Wenhui, et al. "Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020." BMJ global health 7.11 (2022).
[3] Wang, Wenjuan, et al. "Impact of Medical–Pharmaceutical Separation Reform on Hospitalization Expenditure in Tertiary Public Hospitals: Difference-in-Difference Analysis Based on Panel Data from Beijing." Risk Management and Healthcare Policy (2024): 1263-1276.
[4] Cheng HC, Zhang YO, Sun J, et al. Impact of zero-mark-up medicines policy on hospital revenue structure: a panel data analysis of 136 public tertiary hospitals in China, 2012–2020. BMJ Glob Health. 2021;6(11): e007089. doi:10.1136/bmjgh-2021-007089
[5] Du J, Xie J, Qian Y, et al. Impact of China’s zero mark-up drug policy on drug cost of NCDs’ outpatients: an interrupted time series analysis. BMC Health Serv Res. 2021;21(1):404. doi:10.1186/s12913-021-06414-3
[6] Yan K, Yang C, Zhang H, et al. Impact of the zero-mark-up drug policy on drug-related expenditures and use in public hospitals, 2016-2018: an interrupted time series study in Shaanxi. BMJ Open. 2020;10(11): e037034. doi:10.1136/bmjopen-2020-037034
[7] Wu Y, Han X, Qiu J. Impacts of the zero-markup drug policy on hospitalization expenses of patients with stroke in Western China: an interrupted time series analysis. Risk Manag Healthy Policy. 2024;17(null):777–788. doi:10.2147/RMHP.S456977
[8] Faraji M, Sharifi T, Mohammad-pour S, et al. Out-of-pocket pharmaceutical expenditure and its determinants among Iranian households with elderly members: a double-hurdle model. Cost Eff Resour Allocation. 2024;22(1):15. doi:10.1186/s12962-024-00521-8
[9] Selvaraj S, Farooqui HH, Karan A. Quantifying the financial burden of households’ out-of-pocket payments on medicines in India: a repeated cross-sectional analysis of National Sample Survey data, 1994–2014. BMJ Open. 2018;8(5): e018020. doi:10.1136/bmjopen-2017-018020
[10] Jakovljevic M, Timofeyev Y, Ekkert NV, et al. The impact of health expenditures on public health in BRICS nations. J Sport Health Sci. 2019;8(6):516–519. Doi: 10.1016/j.jshs.2019.09.002
[11] Sahoo PM, Rout HS, Jakovljevic M. Future health expenditure in the BRICS countries: a forecasting analysis for 2035. Globalization Health. 2023;19(1):49. doi:10.1186/s12992-023-00947-4
[12] Yi, Z. H. O. U. "New medical reform and the sustainable development of the pharmaceutical industry in China." Chinese medical journal 126.4 (2013): 775-782.
[13] National Healthcare Security Administration of China. Announcement. Announcement of the National Healthcare Security Administration on the Release of the "2025 National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug List and the Adjustment Work Plan for the Commercial Health Insurance Innovative Drug List" and Other Related Documents. July 10, 2025. https://www.gov.cn/zhengce/zhengceku/202507/content_7031575.htm
[14] Sahoo PM, Rout HS, Jakovljevic M. Contemporary universal health coverage in India–the case of federal state of Odisha (Orissa). Risk Manag Healthy Policy. 2023;1131–43.
[15] Pan J, Liu GG, Gao C. How does separating government regulatory and operational control of public hospitals matter to healthcare supply? China Econ Rev. 2013; 27:1–14.
[16] Pan J, Zhao H, Wang X, Shi X. Assessing spatial access to public and private hospitals in Sichuan, China: the influence of the private sector on the healthcare geography in China. Soc Sci Med. 2016; 170:35–45.
[17] Pan J, Lei X, Liu GG. Health insurance and health status: exploring the causal effect from a policy intervention. Health Econ. 2016; 25:1389–402.
[18] World Health Organization, Asia-Pacific Health Systems and Policy Review. Health Systems in Transition. Volume 5, Issue 7, 2015. https://apo.who.int/docs/librariesprovider15/publications/hits/china_health_systems_review_cn.pdf?sfvrsn=d2cffcda_5.
[19] Life Sciences Industry, Digital Transformation White Paper. Case Study: Informatization Empowers Refined Management in Smart Pharmacies. https://assets.kpmg.com/content/dam/kpmg/cn/pdf/zh/2023/08/digital-transformation-of-life-science-industry-white-paper.pdf.
[20] Yip WC, Hsiao WC, Chen W, Hu S, Ma J, Maynard A. Early appraisal of China’s huge and complex health-care reforms. Lancet (London, England). 2012;379(9818):833–42.
[21] Yip W, Fu H, Chen AT, Zhai T, Jian W, Xu R, et al. 10 years of health-care reform in China: progress and gaps in Universal Health Coverage. Lancet (London, England). 2019;394(10204):1192–204.
[22] “Healthy China 2030” Planning Outline: General Office of the State Council, PRC; 2016 [Available from: http://www.gov.cn/zhengce/2016-10/25/content_5124174.htm.
[23] Tan X, Zhang Y, Shao H. Healthy China 2030, a breakthrough for improving health. Global Health Promotion. 2019;26(4):96–9.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2025 Frontiers in Preventive Medicine